<SEC-DOCUMENT>0001628908-23-000170.txt : 20231103
<SEC-HEADER>0001628908-23-000170.hdr.sgml : 20231103
<ACCEPTANCE-DATETIME>20231102201259
ACCESSION NUMBER:		0001628908-23-000170
CONFORMED SUBMISSION TYPE:	S-8
PUBLIC DOCUMENT COUNT:		7
REFERENCES 429:			333-204785
REFERENCES 429:			333-225714
REFERENCES 429:			333-257118
FILED AS OF DATE:		20231103
DATE AS OF CHANGE:		20231102
EFFECTIVENESS DATE:		20231103

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Evolent Health, Inc.
		CENTRAL INDEX KEY:			0001628908
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MANAGEMENT SERVICES [8741]
		IRS NUMBER:				320454912
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-8
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-275287
		FILM NUMBER:		231374142

	BUSINESS ADDRESS:	
		STREET 1:		800 NORTH GLEBE RD, SUITE 500
		CITY:			ARLINGTON
		STATE:			VA
		ZIP:			22203
		BUSINESS PHONE:		571-389-6000

	MAIL ADDRESS:	
		STREET 1:		800 NORTH GLEBE RD, SUITE 500
		CITY:			ARLINGTON
		STATE:			VA
		ZIP:			22203
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-8
<SEQUENCE>1
<FILENAME>a20231102s-8.htm
<DESCRIPTION>2023 S-8
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i9c8365431b7e421ba2c3b5665c5e6d6a_1"></div><div style="min-height:31.5pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:112%">As filed with the Securities and Exchange Commission on November 2, 2023&#160;&#160;&#160;&#160;</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Registration No. 333-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt;padding-left:31.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">UNITED STATES </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</font></div><div style="margin-top:1.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">FORM S-8 </font></div><div style="margin-top:4.5pt;text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">REGISTRATION STATEMENT<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">UNDER </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">THE SECURITIES ACT OF 1933 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%">Evolent Health, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter) </font></div><div style="padding-left:15.75pt;padding-right:15.75pt;text-align:center;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.370%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.453%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.032%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.562%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">800 N. Glebe Road, Suite 500</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Arlington, VA 22203</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Delaware</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">32-0454912</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(State or other jurisdiction of</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">incorporation or organization)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Address of Principal Executive Offices)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(I.R.S. Employer</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Identification No.)</font></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:4.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC. AMENDED AND RESTATED 2015 OMNIBUS INCENTIVE COMPENSATION PLAN</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(Full title of the plan) </font></div><div style="padding-left:15.75pt;padding-right:15.75pt;text-align:center;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</font></div><div style="margin-bottom:1.5pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:90%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Jonathan Weinberg, Esq. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:112%">General Counsel</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Evolent Health, Inc. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:112%">800 N. Glebe Road, Suite 500</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Arlington, Virginia 22203</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(571) 389-6000</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:1.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:80%">(Name, address, including zip code, and telephone number, including area code, of agent for service)</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:15.75pt;padding-right:15.75pt;text-align:center;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</font></div><div style="margin-bottom:1.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:80%">Copy to&#58;</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:37.797%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Elizabeth A. Morgan, Esq.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">King &#38; Spalding LLP</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1185 Avenue of the Americas</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New York, NY 10036</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(212) 556-2100</font></div></td></tr></table></div><div style="padding-left:15.75pt;padding-right:15.75pt;text-align:center;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-right:18pt"><font><br></font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.&#160;See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.476%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.249%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.153%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.741%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Large&#160;accelerated&#160;filer</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated&#160;filer</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-accelerated filer</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller&#160;reporting&#160;company</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.    &#9744;   </font></div><div style="padding-left:15.75pt;padding-right:15.75pt;text-align:center;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9c8365431b7e421ba2c3b5665c5e6d6a_4"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXPLANATORY STATEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This Registration Statement is filed by Evolent Health, Inc. (the &#8220;Company&#8221;) pursuant to General Instruction E to Form S-8. The contents of the Registration Statements on Form S-8 previously filed on June 8, 2015 (File No. 333-204785), June 18, 2018 (File No. 333-225714) and June 15, 2021 (File No. 333-257118) are incorporated by reference herein and made a part hereof, except as supplemented, amended or superseded by the information set forth below. This Registration Statement on Form S-8 is filed by Evolent Health, Inc. to register an additional 4,000,000 shares of Class A common stock that may become issuable under the Evolent Health, Inc. Amended and Restated 2015 Omnibus Incentive Compensation Plan, as amended (the &#8220;Amended 2015 Plan&#8221;). The Amended 2015 Plan has been amended to (i) authorize an additional 4,000,000 shares of Class A common stock for issuance under the Amended 2015 Plan and (ii) authorize an additional 4,000,000 shares of Class A common stock that may be delivered pursuant to incentive stock options granted under the Amended 2015 Plan. </font></div><div id="i9c8365431b7e421ba2c3b5665c5e6d6a_7"></div><div style="-sec-extract:summary;margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INFORMATION REQUIRED IN THE REGISTRATION STATEMENT </font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 6. Indemnification of Directors and Officers.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Section 145 of the Delaware General Corporate Law (the &#8220;DGCL&#8221;) provides that a corporation may indemnify directors and officers as well as other employees and individuals against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with any threatened, pending or completed actions, suits or proceedings in which such person is made a party by reason of such person being or having been a director, officer, employee or agent to the registrant. The DGCL provides that Section 145 is not exclusive of other rights to which those seeking indemnification may be entitled under any bylaw, agreement, vote of stockholders or disinterested directors or otherwise. Our second amended and restated certificate of incorporation, as amended, provides for indemnification by Evolent Health, Inc. of its directors, and our second amended and restated bylaws provide for the indemnification by Evolent Health, Inc. of its directors and officers, in each case to the fullest extent permitted by the DGCL, subject to certain limitations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Section 102(b)(7) of the DGCL permits a corporation to provide in its certificate of incorporation that a director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (i) for any breach of the director&#8217;s duty of loyalty to the corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) for unlawful payments of dividends or unlawful stock repurchases, redemptions or other distributions, or (iv) for any transaction from which the director derived an improper personal benefit. Our second amended and restated certificate of incorporation, as amended, provides for such limitation of liability.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We maintain standard policies of insurance under which coverage is provided (i) to our directors and officers against loss arising from claims made by reason of breach of duty or other wrongful act, and (ii) to Evolent Health, Inc. with respect to payments which may be made by us to such officers and directors pursuant to the above indemnification provision or otherwise as a matter of law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have entered into customary indemnification agreements with each of our directors and executive officers. The indemnification agreements provide the executive officers and directors with contractual rights to indemnification and expense reimbursement, to the fullest extent permitted under the DGCL. The indemnification agreements also require Evolent Health, Inc. to advance expenses to its directors and executive officers as incurred in connection with legal proceedings against them for which they may be indemnified and that the rights conferred in the indemnification agreements are not exclusive.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;8. Exhibits.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.428%"><tr><td style="width:1.0%"></td><td style="width:8.622%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.018%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit<br>Number</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Document Description</font></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1628908/000162890821000066/a20210610exhibit31.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">4.1</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1628908/000162890821000066/a20210610exhibit31.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Certificate of Amendment of the Second Amended and Restated Certificate of Incorporation of Evolent Health, Inc., dated June 10, 2021, filed as Exhibit 3.1 to the Company&#8217;s report on Form 8-K filed with the SEC on June 10, 2021 and incorporated herein by reference.</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1628908/000119312523012645/d331612dex31.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">4.2</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1628908/000119312523012645/d331612dex31.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Certificate of Designation of Series A Convertible Preferred Stock of the Company, dated as of January 19, 2023, filed as Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on January 23, 2023, and incorporated herein by reference.</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="s-8exhibit51.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">5.1</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="s-8exhibit51.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Opinion </a><a href="s-8exhibit51.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">of King &#38; Spalding LLP with respect to the shares being registered.</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="exhibit231deloitteconsent.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">23.1</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="exhibit231deloitteconsent.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Consent of Deloitte &#38; Touche LLP</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="exhibit232kpmgconsent.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">23.2</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="exhibit232kpmgconsent.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Consent of KPMG LLP.</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="exhibit233marcumconsent.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">23.3</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="exhibit233marcumconsent.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Consent of Marcum, LLP.</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Power of Attorney (included on the signature page hereto).</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="http://www.sec.gov/Archives/edgar/data/1628908/000119312523126887/0001193125-23-126887-index.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">99.1</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="http://www.sec.gov/Archives/edgar/data/1628908/000119312523126887/0001193125-23-126887-index.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Amendment to the Evolent Health Inc. Amended and Restated 2015 Omnibus Incentive Compensation Plan, filed as Appendix B to the Company&#8217;s Definitive Proxy Statement on Schedule 14A filed with the SEC on April 28, 2023, and incorporated herein by reference.</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="exhibit107s-8.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">107</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="exhibit107s-8.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Calculation of Filing Fee Table.</a></font></div></td></tr></table></div><div id="i9c8365431b7e421ba2c3b5665c5e6d6a_10"></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES </font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Act, the Company certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Arlington, State of Virginia, on November 2, 2023.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt;padding-left:216pt;text-indent:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.601%"><tr><td style="width:1.0%"></td><td style="width:15.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.423%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC.</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Seth Blackley</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Seth Blackley</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer</font></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each person whose signature appears below hereby constitutes and appoints John Johnson and Jonathan Weinberg and each of them singly, his or her true and lawful attorney-in-fact and agents, with full power of substitution and re-substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto each said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or either of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities indicated and on the 2nd day of November 2023.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:43.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.820%"></td><td style="width:0.1%"></td><td style="width:0.0%"></td><td style="width:0.149%"></td><td style="width:0.0%"></td><td style="width:1.0%"></td><td style="width:16.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signature</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Title</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date</font></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Seth Blackley</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer and Director<br>(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November 2, 2023</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Seth Blackley</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; John Johnson</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer<br>(Principal Financial Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November 2, 2023</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">John Johnson</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Aammaad Shams</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Accounting Officer and Controller<br>(Principal Accounting Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November 2, 2023</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aammaad Shams</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Toyin Ajayi, MD</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November 2, 2023</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Toyin Ajayi, MD</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Craig Barbarosh</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November 2, 2023</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Craig Barbarosh</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; M. Bridget Duffy</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November 2, 2023</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">M. Bridget Duffy, MD</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Peter Grua</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November 2, 2023</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Peter Grua</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:43.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.820%"></td><td style="width:0.1%"></td><td style="width:0.0%"></td><td style="width:0.149%"></td><td style="width:0.0%"></td><td style="width:1.0%"></td><td style="width:16.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signature</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Title</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date</font></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Diane Holder</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November 2, 2023</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Diane Holder</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Richard jelinek</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November 2, 2023</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Richard Jelinek</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Kim Keck</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November 2, 2023</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Kim Keck</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Cheryl Scott</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November 2, 2023</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cheryl Scott</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Tunde Sotunde, MD</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November 2, 2023</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tunde Sotunde, MD</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>2
<FILENAME>exhibit107s-8.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i78ce456116694b41951c169a2ab566d9_34"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 107</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EX-FILING FEES</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Calculation of Filing Fee Table</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Form S-8</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(Form Type)</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Evolent Health, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(Exact Name of Registrant as Specified in its Charter)</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Table 1&#8212;Newly Registered Securities </font></div><div style="text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.004%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Security Type</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Security Class Type</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Fee Calculation Rule</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Amount Registered</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Proposed Maximum Offering Price Per Unit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Maximum Aggregate Offering Price</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Fee Rate</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Amount of Registration Fee</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Equity</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Class A Common Stock, par value $0.01 per share</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4,000,000</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$24.31</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$97,240,000.00</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.0001476</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$14,352.62</font></td></tr><tr><td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Total Offering Amounts</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$97,240,000.00</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$14,352.62</font></td></tr><tr><td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Total Fee Offsets</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Net Fee Due</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$14,352.62</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(1)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to Rule 416 of the Securities Act of 1933, as amended, this Registration Statement on Form S-8 shall also cover any additional shares of Class A common stock, par value $0.01 per share (the &#8220;Common Stock&#8221;), of Evolent Health, Inc. (the &#8220;Registrant&#8221;) that become issuable under the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan, by reason of any stock dividend, stock split, recapitalization or any other similar transaction that results in an increase in the number of the Registrant&#8217;s outstanding shares of Common Stock.</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(2)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Estimated in accordance with Rule 457(c) and 457(h) solely for the purpose of calculating the registration fee on the basis of the average of the high and low prices of the Common Stock as reported on The New York Stock Exchange on October 31, 2023.</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>s-8exhibit51.htm
<DESCRIPTION>2023 S-8 EX-5.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i9d3083d714fb48be9921ce51c09f0f99_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.06pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:133%">Exhibit 5.1</font></div></div><div><font><br></font></div><div style="margin-bottom:0.06pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.75pt"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:23px;margin-bottom:5pt;vertical-align:text-bottom;width:299px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">                                                                                   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">King &#38; Spalding LLP</font></div><div style="padding-left:329.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;1185 Avenue of the Americas</font></div><div style="padding-left:329.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New York, NY 10036-2601 </font></div><div style="padding-left:329.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tel&#58; +1 212 556 2100</font></div><div style="padding-left:329.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fax&#58; +1 212 556 2222</font></div><div style="padding-left:329.75pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">www.kslaw.com</font></div></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2, 2023</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evolent Health, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800 N. Glebe Road, Suite 500 </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arlington, Virginia 22203 </font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ladies and Gentlemen&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We have acted as counsel for Evolent Health, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221;), in connection with the registration statement on Form S-8 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Registration Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221;), filed by the Company with the Securities and Exchange Commission (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Commission</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221;) under the Securities Act of 1933, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221;), relating to 4,000,000 shares of the Company&#8217;s Class A Common Stock, par value $0.01 per share (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221;), issuable pursuant to the Evolent Health, Inc. Amended and Restated 2015 Omnibus Incentive Compensation Plan (as amended, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">Amended and Restated 2015 Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221;).</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In that capacity, we have examined originals, or copies certified or otherwise identified to our satisfaction, of such documents, corporate records and other instruments as we have deemed necessary or appropriate for the purposes of this opinion, including, without limitation&#58; (a) the second amended and restated certificate of incorporation of the Company, as amended&#59; (b) the third amended and restated by-laws of the Company&#59; (c) certain resolutions adopted by the board of directors of the Company&#59; and (d) the Amended and Restated 2015 Plan.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In rendering our opinion, we have assumed the genuineness of all signatures, the legal capacity of all natural persons, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified, conformed or photostatic copies and the authenticity of the originals of such latter documents. As to all questions of fact material to this opinion that have not been independently established, we have relied upon certificates or comparable documents of officers and representatives of the Company.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Based on the foregoing and in reliance thereon, and subject to compliance with applicable state securities laws, we are of the opinion that the Shares when, and if, issued pursuant to the terms of the Amended and Restated 2015 Plan will be validly issued, fully paid and non-assessable.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We are admitted to practice in the State of New York, and we express no opinion as to matters governed by any laws other than the laws of the State of New York, the General Corporation Law of the State of Delaware and the Federal laws of the United States of America. </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We hereby consent to the filing of this opinion with the Commission as Exhibit 5.1 to the Registration Statement. In giving this consent, we do not thereby admit that we are included in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission.</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Very truly yours,</font></div><div style="margin-bottom:0.06pt;padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#47;s&#47; King &#38; Spalding LLP</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>exhibit231deloitteconsent.htm
<DESCRIPTION>EX-23.1 S-8
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="iefe01226372643b38e69d83a9a468d73_34"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in this Registration Statement on Form S-8 of our reports dated February 24, 2023, relating to the consolidated financial statements of Evolent Health, Inc. (the &#8220;Company&#8221;) and the effectiveness of the Company's internal control over financial reporting, appearing in the Annual Report on Form 10-K of the Company for the year ended December 31, 2022. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Deloitte &#38; Touche LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">McLean, Virginia</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November 2, 2023</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>5
<FILENAME>exhibit232kpmgconsent.htm
<DESCRIPTION>EX-23.2 S-8
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i479ae0951fd545bda5a3a5a256c60d02_34"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.2</font></div></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consent of Independent Registered Public Accounting Firm</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the use of our report dated September 25, 2023, with respect to the combined financial statements of Magellan Specialty Health, which report appears in the Form 8-K&#47;A of Evolent Health, Inc. dated September 26, 2023.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; KPMG LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">St. Louis, Missouri </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November 2, 2023</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.3
<SEQUENCE>6
<FILENAME>exhibit233marcumconsent.htm
<DESCRIPTION>EX-23.3 S-8
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i5c135b4d82c14d5b900c9a435fa12c03_34"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.3</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM&#8217;S CONSENT</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We consent to the incorporation by reference in this Registration Statement of Evolent Health, Inc. on this Form S-8  of our report dated October 31, 2023, with respect to our audit of the combined financial statements of Magellan Specialty Health (a business of Magellan Health, Inc.) as of December 31, 2022 and for the year then ended, which report appears in the Current Report on Form 8-K filed by Evolent Health, Inc. with the SEC on November 2, 2023.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#47;s&#47; Marcum LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Marcum LLP</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">New York, NY</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">November 2, 2023</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_0a.jpg
<TEXT>
begin 644 image_0a.jpg
MB5!.1PT*&@H    -24A$4@  "-,   "O" (   !21IUQ    "7!(67,  5MI
M   :Z0&VZYOF  !__TE$051XG.S=>5Q-^?\'\+GMI4V%(D8*842VQFY&UI*(
M1C%%QEH1W^S?[ V)+[(O+9:(**0FV;-364N1+;L:+4)2=WZ?Z3Q^OO?KJCGW
MWG/OYW9Z/?_X/KZ/A^G>]_MS/N><]^>\[SGGN[\                 N/ =
M[0                " )]!Y @               &Z@\P0
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M4U/34:-&B>Y-H:&A65E97(W5RY<OHZ.C?7Q\6K1HT:!! T]/SXB(" 7<904
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M"^F @ !;6]NJ<S$V-N[7K]\$$4N7+OWFPN3)DR?D<.'BXO+]]]^+?PXZ3P
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MO!D6%M:[=V_I=ADK*ZM=NW;1SD-Q'CQXL'CQXF[=NM6K5T^Z$4/G"0
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M@<X32$>6SE.C1HV"@X,?/GQ86%A(.P]%*RDI>?[\^:%#AZ1X2B$Z3P
MP#_H/%% EJ:7+U]>OWZ]O;V]>+Z:FIH__OBCKZ_OB1,G:$<*  !0O<GRG+TY
M<^:04S;M#*147EY^\.!!3T_/-FW:L$E65575Q<5EY\Z=-V_>I!T[T/'NW;MS
MY\X%!P=WZ]9-NEW&TM*R1CUG3]SCQX_7KET[:-"@1HT:L1\W=)X      (!_
MT'FBX.W;MV1DS,S,:M6J)9ZOD9%18&#@BQ<OBHN+:4<*  !0O=78SA-16%CX
MY,F3J5.GLDE6(!#HZ^LW;MPX)"2$=N! 1TY.CI^?GZFIJ=2[##I/I:6E>7EY
MB8F)??OV93]NZ#P!      #_H/.D4"4E)<G)R4%!03U[]OQFICUZ])@Y<^;9
MLV=I1PH  %"]I:6E;=FRQ=G964-#0[H*I+IWGOZ2_)E[9*P" P-I1PUTR/*<
M/08Z3XRG3Y]NWKS9U=6U<>/&;,8-G2<      . ?=)X4ZNW;MS-GSC0P,/CF
M>\Z-C8U7K%A14%!0W:]S 0  4!<2$F)F9J:MK2W%&YX8Z#Q!C8+.$U?(?E=<
M7'SV[-D! P:P&3=TG@      @'_0>5*0CQ\_GCQY<M&B15V[=A7/45M;NW?O
MW@L6++APX0+M2 $  /A@Q8H54C\TC('.$]0HLG2># T-!PX<2"KVU-14VGDH
MBV?/GH6'AWMX>%A9654]>N@\ 0      _Z#SI"!__OFGGY^?NKJZBHJ*>(XF
M)B9KUZXM+2TM+R^G'2D    ?H//T%SI/( E9.D]-FC0)#P\GQ3]*V2^$0B'9
M :]<N>+HZ%CUZ*'S!       _(/.D]Q]^/ A(2%AUJQ9=G9VXMEI:VL/'#@P
M*"B(K$MI1PH  , ?Z#S]A<X3L).?GQ\;&^OGY]>V;5OI=A9+2\N=.W?2SD,9
MI::F.CDY53UZZ#P!      #_H/,D7V5E9:]>O?+V]OYF:JJJJJ:FIALW;J0=
M)@   -^@\_07.D_ #B=O>$+GZ9O2TM*&#AU:V6,/&.@\ 0      _Z#S)$?O
MW[\_=.B0CX]/NW;MQ//2T=%Q=G9>MVX=69'2CA0  (!OT'GZ"YTG8 >=)_EY
M]>I53$S,U*E36[9L6=GHH?,$      #\@\Z37 B%PO?OWS]X\&#\^/'B&0D$
M AT=';)$W[IU*^U( 0  ^.;CQX_Y^?F+%BW2UM:6I0)!YPEJ"'2>Y.WFS9MN
M;F[Z^OKJZNKBHX?.$P      \ \Z3W+Q_OW[_?OW>WEYM6[=6CRC6K5JN;JZ
MAH:&WKIUBW:D    ?'/\^'$_/[_.G3NKJ:G)4H&@\P0U!#I/\O;FS9N$A(39
MLV=_<VF SA,      / /.D\<*R\O+R@H2$]/'SMV;&49&1L;AX2$T(X4  "
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M$#L[.]'10^<)      #X!YTG#N3GY_OY^546OYJ:6I,F308,&! ='4T[4@
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MKT-$N;BX[-NW[\Z=.\I\YY-0*$Q/3X^.CAX^?#B;I/"</>"J\\2PLK+",_<
M:JRG3Y\F)26)EG97KUY]]^X=[;@   "@1GOY\N6I4Z>XO7Y5F4N7+A44%-#.
M6"F@\R2EHJ(B$E6S9LV,C(S$8];7UY\S9TY65A8>V@X /):4E.3DY-2"4].G
M3W_PX 'MS( /Y-%Y,C8VMK:V7KUZM3+?^51>7KYV[5H2IXF)"9NDT'D"=)X
M@"OQ\?$#!@P0+>W\_?W)089V7    %"CG3Y]>MBP8=Q>OZJ,KZ]O9F8F[8R5
M CI/$BLM+;UV[=KFS9O[]>LG'JV&AD:'#ATF3)AP[-@QVI$J6G%Q\<6+%W?6
M>$>.''GRY GMK0' C9R<G+BXN,IF^Y0I4QHV;"C[<5Z4G9W=\N7+J][+SIT[
M5UA82'ML0-G%Q\>/'3NV7;MV:FIJW,[208,&A8>'7[]^7=GN?!(*A3=NW-BQ
M8\?@P8/9)**BHM*V;=O1HT<?/GR8=NQ $[>=IWKUZDV<.#$V-O;APX>T,P,
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M@%6-N(X=.WI[>S-[)?/ 4C8Q)R0D^/XOEJ=%@4! ]GUFUUB_?OW5JU?E/;S
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M,_DC_ RDH*!@]NS9:FIJ'SVE!2Z%\,[+RXNQGW&A(UZ\> %QY^C1HU'U,JS
M,)R(<;5HT2+&:HUGSIQQ<G+2X0 F.))CVEAY$B=V[=IE:&@X9,@0&JNQ0YX
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M'5N4)P*P?<&"!8:&A@C+"8 '4E-3'SUZU-751;=]@D!=>2+X]MMOQ:9@E&B
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M)+9@Y8D7:)4G&1D9=75U6UM;2/'HMNR_8.4)%:)7GN3DY+2UM=W=W6G7;\C
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ML[/?O'D#@6]$1 3QO[BXN"!1A84$M W6,<()$$T5%!2@<C*$>9!1;-RX$3S
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M2TA(H.97R04K3]3AI3Q!D/?^H&Y149&;FQMU/Y/!R<F)4=5RF:8\2<Y'#2:
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MHU[YOQ L635!3T^O6[=N@YJ!=:G%T__X,T^0;A44%%Q1 :1V145%?/PNHDO
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MI0N[G1,G3LS)R2'U*WR<N3=SYDR1?"5+>- \20@T3]J"YDD5:)[8O4'*/#'
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MV6,#U0'Q-P7=W=T7+UY\_/CQBHH*/MHL3M \20@T3]J"YDD5:)[8O<&'>6*
M_1IV[?GSYQ,_)%:9KEV[3ILV+2$A(2\OCTN;T3S1XL&#!SMW[N1^+XMATJ1)
M KQ!U;=O7UACN;0S)25%\Z1+DN;)V-AXX\:-_+6\=4#&MG3I4B,C(WUR!X)#
M-KEMV[:&A@:1' ).%S1/W!'2/+&Y>O4J_"[DRJ\='\\'0X<./7_^?&-C8RN>
MTT3S)'4.'SX,FVA[%H:&AL0?7H9%'I;Z]FJ9.W<NP>^%M@4@9ZBOK]^T:1.:
M)^[ Z@?I(,Q# P,#4M->&?C[Z]:M@U&#L:,=,8+0)RLK*S PD&RJ@^9)BL $
M@&G ) /^_OXB3\.4WW9BX,\\'3ITJ$^?/GRD9VWMFT]HGB0$FB=M0?.D"C1/
M[-[@SSPQW+IU"_9Q8>YB#1@PX-2I4ZV[B\6 YDDW@"G=OW]_/NYEL>]BS9@Q
MX^'#AX(%A>:)&/7U]1<O7ERW;AW!JPXBA;4#TI3+ER_3CH\^:)ZX0\L\%186
M'CUZ=/'BQ0(\,^+@X #5<GQ\?"L^C8#F2>K<OW]_SYX]6UA,FS:-2%G.QLO+
M*R(B8HM:SIT[AV\R:45Z>CKTZO#APR&YYS(Z:)[^V_SF$Z0-FS=OYO7(4P,#
M U@PER]?+D!)@R#BIZRL[,2)$Z&AH2W>QV\=:)ZD2*]>O98L6<(D \>/'R\I
M*:$]8NH0WCS=NW</4C4^TC,T3ZT#S9, H'G2%C1/JD#SQ.X-OLT3[.#P]V%/
MAYV=U BJPL[.+B @8/OV[0\>/&A=:]$\Z0:YN;EPC3-IY(P9,VQM;4GUJH>'
M!U3NS%^&^D+(U\0E9I[T]/1,3$SL[>UC8V/Y:SD78/ @>R,;M965571T-/SE
M^OIZVO'1!,T3=VB9)X;KUZ_#;MJA0P=#0T/NXZ@>'Q^?DR=/5E55-34U:=Y"
M6N8)?M?7U]?"PH+X"PIMS3PIDYR<#)/<S,R,X-NH,V?.;(.?$^";K5NWPN+
M?730//V!7"Z/BHJ"%,+8V)A[QZK"R,AHU:I5+UZ\J*NKHQTQ@M#GUJU;!+_\
M!"7BH4.'*BLK&QL;:4?V)VW3/$'N"IN4E09,F3+E]NW;M$?IS<"D^NVWW_;N
MW?O:*9'MVK7KV+'CG#ES6GWS2Q/X.'-O\N3)< %65U>WD6\]HGF2$&B>M 7-
MDRK0/+%[@V_SQ ![.NSLD -P?#Y2$]YYYYWDY&1(_+2ZB\6 YDGW4/5X4.N
M:<QK:J<&B9DG2/K]_?UW[=HEVH2>#_/4OGW[(4.&+%NV[,<??Z0='TW0/'&'
MKGDJ*2F!WX*9[.;FQGT<U6-G9_?^^^_'Q,3DYN9JWD):YNG)DR>0,RU:M,C)
MR8EL/Z!Y>OCP(5SO<^;,(7A:+IHG/D#S1!R%0G']^O7X^/BQ8\=R[UA5Z.OK
M#Q@P ):O<^?.T8X80>A#UCQ96UN/&3-FPX8-=^_>I1W9G[1-\P25__+ER_^M
M 6?.G"DK*Z,]2F\&\L/(R,A1HT996EJR(_7T]%R]>O6%"Q=X?1B6#_/DXN(R
M=>K4;[[YIKR\G+^6BP<T3Q("S9.VH'E2!9HG=F\(8YY@3X>=/3P\O&_?OJ3&
M414V-C9^?GZ;-FVZ=^^>MNU$\Z1[H'EZ,V3-DYZ>7L>.'2&AC(^/YZ_-W*FL
MK(1DO6O7KN;FYJ1B9["RLEJ_?OVS9\^JJZMI1TD'-$_<H6N>_FC#M&G38$]M
MW[X]]]%4S\"! Y.2DDI+2QL:&C1I&RWSQ,#'F7MHGAC(WN! \\0':)YX0BZ7
M;]FRI5NW;AP_H*4>6,\W;-A .U8$H4]V=O9''WUD:VM+\%U#L9VY1\H\&1D9
M03;832+,F#'CSIT[M/N>),G)R7WZ]%$>%_[.V6.3DI(R=.A0*&^)O^X_:]:L
M-I*DH7F2$&B>M 7-DRK0/+%[0QCSQ)"5E35[]FRR"9XJ/#T]#QPX4%)2HM6I
M5VB>= \T3V^&K'DR-#2$//B[[[Z#BHZ_-G.GL;'QYY]_WK%CAZ^O+ZG8&=JW
M;^_M[;UPX4*XL&E'20<T3]P1@WDJ*RM+2TM;M6I5B^4N66QL;$:-&A45%77_
M_GU-VH;F25=!\R1^T#SQA$*AN'/G#M2H!-_#4 ;-$X(PO'CQXM*E2^O6K>O?
MOS^IZTM7S9.;F]O*E2OW2X0??OCA^?/GM/N>)'3-4WY^_HD3)X*#@R%7YSZ7
MV*!YTA8T3P* YDE;T#RI LT3NS>$-$_EY>47+UY<NW9MOW[]2(VF*JRMK2'1
M@M_2ZI5W-$^Z!YJG-T/*/.GIZ<&%Y^[NGI"0P%]KR<+'F7L,M/9+,8#FB3MB
M,$\,-V_>G#-GCJ.CHZFI*?<Q5<^  0/V[]__Y,F3VMI:]:U"\Z2KH'D2,U!;
MYN;FKEBQ@LB[PFB>6D0NEV_;M@VV/RLK*^Z=K(R1D5%H:"B,8QLYXPA!U'/O
MWKT%"Q9T[][=S,R,^_6EJ^9I^/#A;?P@<5J\?/DR/S\_-C:VQ=1H].C1,-_N
M"\+FS9NA%N ^E]CX^_M#/E]45-2*CV1("S1/$@+-D[:@>5(%FB=V;PAIGACN
MWKT[?_Y\4@F>>CP\/';OWEU04*!A;8OF2?<X=^[</_[Q#WM[>ZBUN?<JFB=U
M&!H:3I\^_<2)$UI]KX4N:)[X ,T3=\1CGLK+RV%KA-39W=V=^YBJQ]K:>NC0
MH9#NO_&-231/N@J:)S&3FIH*NSQ4#K#=<Q\=-$\MHE H<G)RDI.3 P,#N7>R
M,OKZ^KU[]YX\>;+ Y1^"B)/??OOMZM6K6[9L@2R+^_6%Y@DARY4K5Z!0A9RS
MQ5-8[>WM(?O]IR# W"9^\\[1T?&]]][[ZJNO2DM+:?<TOZ!YDA!HGK0%S9,J
MT#RQ>T-X\U1140%[:'1TM*>G)ZDQ5865E96/CT]X>+B&A_VB>=(]GCU[EI:6
M]MEGGSDX.'#O531/ZI#B$2Y5556;-V]V=W<G^$U[ADZ=.JU8L2(K*TL2GZXE
M"YHG[HC'/#' )KI@P0(8$>+?15/&R\LK(2$A-S?WY<N7JMJ#YDE70?,D9DB=
ML\> YDD-9(]!5L;(R&CQXL6W;MTJ+BZF'2N"T >N!=B%N5]9:)X0LJ@Z9T^7
M&#=NW*E3IR!;:VQLI-W??('F24*@>=(6-$^J0//$[@WAS1-#3DX.K)RNKJX$
M:UA50(QQ<7$/'CRHJJI2WRI:YNGZ]>LPPUU<7 @^2H+FB0VI,_?0/*E#BN:I
MJ:GI_OW[D-83_ZP"9!MN;FZ3)DV"9)IVE$*#YHD[8C-/4.= DV)B8CP\/+B/
MK'HZ=>H$P8:%A4'*HJH]:)YT%31/8@;-DV#P;9YD,AE4'>/&C4M*2J(=*X+0
M!\V3>M \T:(MF"=[>_NA0X=NV;*EI*2$=G_S!9HG"8'F25O0/*D"S1.[-VB9
MI\K*RILW;V[?OMW;VYO4R*JB8\>.GIZ>(2$A;[RK0\L\E9>79V9F;MRXD6!J
M@>:)#9HG=;1E\\105545&QL[:- @R'VY]P,;2TM+6'JN7KU:5%1$.TKA0//$
M';&9)P;((6 ^N[N[P[;*?7S5X^'A 2E"5E86I O*+4'SI*N@>1(S:)X$@V_S
MQ&!D9#1OWCQ8.9\^?4H[8@2AR<.'#\/#P_OW[\_Q^VIB2-78H'F2.FW!/#',
MFC5+AQ,V-$\2 LV3MJ!Y4@6:)W9OT#)/#/?OWP\+"_/P\.C4J1.I\55%W[Y]
M8V)B;M^^75%1H:H]M,P3 ]DS]] \L4'SI XT3] #CQ\_/G/F#/'/*A@:&O;L
MV7/<N'$I*2FTHQ0.-$_<$:=YJJJJNGOW+B2"7EY>W,=7/1TZ=(!M&Q+9%D_+
M1?.DJZ!Y$C-HG@1#&/,DD\F@*H;*!ZX[VA$C"$U@+<K)R=FS9X^/CP^7:TH,
MJ1H;-$]2!\V3;H#F24*@>=(6-$^J0//$[@VZYJFZNAK2O%V[=@T:-(C4^*K"
MPL("-N[@X.#KUZ^K:@^:)UT%S9,ZT#PQ\+%K,MC8V,3'Q]..3SC0/'%'G.:)
M(3L[.SP\?.# @1P?#=8$=W?W39LV969FPN7);@.:)UT%S9.80?,D&,*8)P9C
M8^.-&S?2CAA11UU='=3P9UA<NG3IV;-GM-NE:\ NS/',/?&D:@QHGJ1+<7$Q
MI+4K5ZYT='3D/H+B!]+X??OVP4('RQWMOB</FB=5/'KTZ-RY<^S=+3<W5Z%0
M4&P2FB=M0?.D"C1/[-Z@:YX88'F!JWM,,X,&#;*VMB8UULKTZM4+5@!F6;MZ
M]6IY>3F[);IDGCP]/;=NW7K]^G4=VYY:!YHG=:!Y8D#S1 HT3]P1LWFJJ:G)
MR\O;NW<O<?NBC+FY^5MOO35W[MS7K R:)UT%S9.80?,D&&B>$#9%146K5Z_V
M8.'GYY>:FDJ[7;H&FB=5H'D2GK2TM,# 0"<G)ZBON8^@^.G4J5/OWKV_^.(+
MG3R@'LV3*O;LV>/M[<W>W>+BXB %HM@D-$_:@N9)%6B>V+TA!O-46UO[Z-&C
M6\TD)B8.&3*$U%@K8VIJZNSLS"QKLV?/OG;M&KLENF2>+"PL7%Q<%BQ8D)65
M)4S[Q0R:)W6@>6*HKJZ&[ =J3E@CN/<&FPX=.GS\\<>G3IUZ_/@Q[2B% ,T3
M=\1LGACNW[^_=NW:X<.'0VK(?:S5TZ=/G\C(R/3T].?/GS._3M<\0;*R8L4*
M'Q\?@B<%>WEY;=JT*2,C0\=*2FU!\R1FR)HGV&UAN*$RH7N+03PH%(KL[.SD
M9I*2D@(" DAUM7K:M6LW??KTE)046@DN\D8*"@J@:F6/FK6U]<*%"\^<.0/_
MB7;K= <T3ZI \R0DSYX]NW#APM*E2QT<'-BCT+5K5U]?WT#1X.WM;69FQGUV
ML9DU:Y9.KFEHGE3QY9=?0A+"CC$B(J*IJ8EBD] \:4YC8^/MV[?W[=LW=NQ8
M[CW&8&1DY.'A,6?.G'/GS@D?$9HG4HC3/+')R\N#*W3DR)&VMK:D1EP5KJZN
ML*I<NG2IM+24^75=,D\,>.8> YHG=:!Y8I#+Y; 69&9F$K$F;/3U]6UL; 8/
M'MQ&/ J:)^Z(WSS5U=4]??KTX,&# IR6:V)B N7WS)DSH5N87Z=KGFIJ:J P
M3DA(@!2*5(Q0O3LZ.@8'!^?DY @3A3A!\R1FR)JG3ITZP5AOVK1))X_6:060
MA&S;MNWM9EQ<7 0XSI1!3T_/VMK:W=U]UZY=M/L :1EE\V1H: BE,A3,HBKC
MI0Z:)U6@>1*2\^?/0PE@9V=G9&3$'H71HT?#['H@&F#[[M:M&_?9Q0;-DWK0
M/ D FB?-J:JJ6K]^O;.SLZ6E)?<>8X#L=_7JU7EY>52F.IHG4HC?/-77U\-P
M)R<G#QTZE-2(J\+8V-C!P6'JU*E_N!DT3[H*FB=UH'EB4U-3<^# @<F3)[NZ
MNG+O$S9MY\P]-$_<$;]Y8LC-S8V.CH9BN$N7+MQ'7#UN;FXK5Z[\IIFPL# 7
M%Q?V?Q72/#&</GW:V]N;;(QXYAZ:)S%#UCPQX)E[?R"7RU>M6J6JHV0RF8>'
M!^RM??OV)3L$#"8F)K"8T^X#I&64S1-#]^[=]^W;1[MUN@.:)U6@>1*2HT>/
M]NG31WD4/OC@@^SL;-JM^Y.,C S8P?_VM[^9FYMSGV,,0X8,B8F)N7SYLHXE
M!FB>5('F2=)45%3HS#E[#&B>2"%^\\20F9E)\(T]];BXN(2%A3'WLF"AZ]6K
M%_N_"FF><G)R8'7R]?6UL;$A%1WD+5#&IJ6EE965"1.%.$'SI XT3VP@VX"4
M[N[=NRT6^5Q \Z0M:)[8O2&VVQD,#0T-L+L<.W;,Q\>'^XBKQ\C(R-K:NFLS
M\'^\]B@HFB?= ,V3F$'SQ"OJS9.!@0&4*S"?%R]>3'8(&- \B1DT3\* YDD5
M:)Z$1"KFJ;:VMKBX.#8VUM'1D?L<8X"=J$N7+J&AH;_^^BOM^$B"YDD5:)XD
M#9HG]:!Y8O<&FB<C(R/8"%3=RQ+2/#%W\ X?/DSP7E;[]NWAXIT^?7H;OY>%
MYDD=:)Z4>?'B!?&;.^;FYI,G3]ZW;Y^HR@8^0//$':F8)X:\O#RH/"=,F #[
M*/=Q;QW"FR>XD*.CH_W\_ A^Z0K-$YHG,8/FB2<4"@54/G%Q<6/&C%'N(IE,
M!H4!Y"1GSYZ5R^4G3YZ</W^^IZ<GV8%HUZZ=O[__U\TD)"3<NG6+=J\@?Z+*
M/%E964&ZE9B82*LXT3&XF"?(!" ?@*S@[MV[M./X$S1/4D39//7LV7/2I$F[
M=NTJ*BJBW;K7@?4'FL=]CK&!Y4['SMQ#\Z0,K+<[=NR )=? P( =(YHG"4'6
M/!D;&P\=.C0L+"P]/9U61&B>2"$5\_3++[] X;.@F8"  .)'R&J.D.:)@8\S
M]T:/'GWUZE4AHQ ;:)[4@>9)&3[,DTPF,S$Q<7%QV;-G#^WX^ 7-$W>D99Y@
M#7GY\N7ITZ<%."=7%<*;)ZB+(.JDI*3^_?N3B@+-$YHG,8/FB2?D<OF77WYI
M:6D)>91R%QD8&$1$1$!Y7U]?_]_F;^R5EI:&AH:2'0@]/3VH^2V;L;.SBXV-
MI=TKR)^H,D^06)J:FO;KU^_0H4.TVZ@+<#%/'AX>AP\?AJR [CW3UT#S)$64
MS1-,RXR,#-@K8;.@W;K70?.D"6B>E(&4TL;&!A*/UV)$\R0AR)HGN$8V;]Y<
M65G9T-! *R(T3Z20BGGZ_???JZNK*YI)2TM[]]UW28V^MJ!YT@W0/*D#S9,R
MM;6U*2DIBQ8M(GA/F<',S Q6X:^__OK.G3NTH^0+-$_<D99Y8LC/S]^Y<R>L
MDE2>%A'>/#&0/7,/S1.:)S'#AWD:-FP85.8__OBCJ&[7"H9"H8"%*SHZNL52
M1R:3#1DR9/GRY5 ;L/]7<KG\[-FSH:&A P<.)#L<#'CRGMA099X8G)R<VNRM
M#;)P,4_B3-+0/$F+W-S<??OVS9@QP];6EMW_@8&!HGJ7C@U<-5#^CQT[MF/'
MCMQG&H.7E]?*E2MAFZNJJJ(='QG0/"FC?,X> YHG25!?7__##S^L7;N6X'G[
M=,_98T#S1 JIF"<V3YX\V;U[]_3ITR&O)C4'-$=X\Y27EQ<?'S]QXD1[>WM2
M4:!Y0O.D#C1/+2*7RXN+BQ<L6,"]9]CHZ>D9&!AT[=HU(2&!=HA\@>:).U(T
M3PJ% A:3BQ<O#A\^G/OH:PN:)]T S9.8X<,\Z>OK0W&^8L6*VMI:VO%1X-6K
M5VO6K($>@'Y0[AS(%N"_-C8V*C_G#O^?ZNKJY<N7DQT.!C1/8@/-DS"@>5(%
MFB=A.'[\>/_^_6'EAVJ1W?]B-D^PBS4U->W;MZ]'CQ[<9QJ#3"8S-#0,"@IZ
M\N0)[?C(@.9)&31/DJ:BHB(T-%15^MHZT#SI$E(T3\R]K,N7+[_WWGNDYH#F
M"&^>F.W[[-FS@P</)A4%FB<T3^I \Z2*VMK:TZ=/+UNVC."=908;&YM___O?
MM./C"S1/W)&B>6(H*"B '&O6K%D"/RU"RSP]?/@P(2%AZM2I1)X6@3D_;]Z\
M0X<.B? H?V% \R1FKERY$A45!>GX:]]$Y0[LLVW-/$%Y<^G2I=6K5P\;-DRY
M0V0RV8@1(]:N7:OFL/O&QL:5*U>2'0@&0T/#4:-&P5AG9&0(V2>(*M \"0.:
M)U6@>1*&HT>/]NW;E]WSO7KU"@X.3DI**BTMI=TZ=>S?OQ_/W%,#FB<V4*^M
M6[<.EJ86I06:)TE045$!LY%[+[%!\Z1+2-$\,< <2$Q,A&G@[.Q,:B9H@O#F
MB2$M+6W(D"&DHH!."PH*.G#@ '2C\+&( 31/ZD#SI)[R\G+BWWR"G34N+@[R
M*DAN:,=''C1/W)&N>6+XZ:>?1HT:I?S8)G_0,D\,9-]\@J'/S,R4R^4*A8)6
M1+1 \R1^^'CS*30TM+*R4H1?L. )B+2AH2$B(J+%WM#7US<V-HZ*BE+_1QH;
M&R%Y,S0TE,ED9(>#P=34=./&C;J:J$@+]>:I>_?N>_;L@60>1XHCK3-/S&$&
M@P8-.G/F#.T(7@?-DU2 BQ<NX:2DI->^\"3FMYW80/(&51ML7@33?DCAH*+4
MC608S1,;56\[,:!Y$C]P59:6EBY:M(A[+_T!K!YV=G;4G\Q&\T0*Z9HGALS,
M3#\_/R'O9=$R3_"CD..1C;0MO_F$YDD=:)[4PX=Y,C4U]?7UC8R,U,EK$LT3
M=Z1NGB!O.WSX\/SY\XD_ JD*73)/SL[.4&]#JEI86$@K(EJ@>1(_?)@GN'Q"
M0D+@.FH+7WM2*!3GSY]?MFQ9BX<;R&2R]]Y[;_/FS5>N7%'_=Z#R3T]/CXJ*
M&CER)-GA8# T-(12)"(B N\X4T>]>8+K<>S8L9"!W[AQ@W9+I4WKS%/7KEUA
M=/;OW__X\6/:$;P.FB>I\)___ ?VUO'CQUM;6[-[7BKF*3L[.R$A8?+DR596
M5MSG&T/?OGWGS9MWY,@1'7 M:)[8H'F2-'5U=2=/GOSDDT\\/3VY]Q*#J:GI
MA D3XN+B;MVZ13<Z-$^DD+IY*BHJ2DY.7KAPX=MOOTUJ/JB'EGF"$N/@P8,?
M?_PQ3%=2L:!YXMZ':)[4H:OFZ<6+%V%ALU%Y^P  !_=)1$%485#8$S]?J'/G
MSE!F5%55-38VTHZ2)&B>N"-U\\20D9'Q_OOO=VS&S,S,P," ^ZQ0!5WS=.'"
MA9$C1T+>3/"TZ_'CQU//OX4'S9/XX<,\,4 ="XD^U+0Z\("S*NKKZYFDHL4>
M@#S*RLIJ\^;-FO]!R!\B(R-AC87_+1^#8F)B G^_LK*RH:&!CPZ!L881_ZT9
M_GY%ZJ@W3PR.CH[Q\?&ZEU(*2>O,DYC3,S1/4D'YG#T&J9@GAL.'#WMX>,"N
M0?!-7%CZ=.!K3VB>&" %@O:O6K4*S9-TX>.</6MKZ[BX.-J1_0\T3Z20NGEB
M^/GGGP," OB^B\5 RSPQD#US#S)/^(,U-35MYSB3/T#SI XT3^J!) DJM^CH
MZ!8_QL %2,WA;ZY8L8+B'7,^0//$'=TP3X6%A2=.G(AK9LF2)2XN+MQGA2KH
MFJ>"@H+DY.3@X&!'1T=2$:%YX@Z:)S[@SSQY>'C,G3LW)25%5V^=*Q0*6,87
M+%C@Y>6E'+Y,)H-E/SX^'M9_S?_FJU>OKEZ]&AL;R]/G< T-#0</'AP2$@(E
M!!]]4E=7=_3HT87-?/;99Y<N7>+C5Z2.)N;)PL("*KTOOOCBVK5KM-LK5= \
MJ0+-$]_HAGEZ\.!!8F(BI%Y$+ L#FB<V4C=/Y\^?_^233P8.'*C&3:)Y$CEH
MGC0'S1.[-Z1HGDI*2E)34Z$\Z=6K%ZE9H0I=,D_=NG4+" B B[H-WH=!\Z0.
M-$^: +LL9$)=NG0Q-37EWE=L8*^%?BLN+JZIJ:$=)1G0/'%'-\P3FQ]__''$
MB!'<9X4JZ)HGAN^__W[LV+%65E9J'N73'%]?WW/GSI67E[>%\\?^ ,V3^$E(
M2'!U=>W0H0-/)U^'A875UM;2CI(\55554- N6;*DQ:@M+"P@3=^V;5OK_CBL
M$ALW;K2SLS,W-^=C4$Q,3"!1+"PLK*ZN)M4AKUZ]JJRLO'?O7E!0$/,K'3MV
M;'4/Z#::F"<&!P>'?_WK7U JZ^1%Q!]P!<%N"WLN[+S:7AUB3L_0/(F?NKJZ
MTM)29F-E][FQL7'GSIWGSIU+Z]9#J]F_?S_!H[8G3IR8F9D)9;BD'YU&\\00
M%17UQA()S9-H8=*VG)P<@FY&)I-![O?7O_Y5)(8&S1,I=,,\,=R\>7/:M&G6
MUM;$3\!B0]<\0;HX8<($V*>(W,5B@-0Q-345LFM=?:*T1= \J0/-DR8T-#1<
MNW8-$D<B)1P;*"T&#1H$J:3./.J+YHD[:)ZT10SF";+54Z=.A82$.#DY<8^H
M6[=NX\:-BXV-+2@HH!N7D*!Y$C]0<QX\>!#R(=B\2(T4&YTT3PJ%(B4E!2:D
MN[N[<LA0>$-Y!M7IG3MW6O?W7[UZ!771[MV[_?S\^!@4 P,#+R^ON7/GGCU[
MEE2?U-75P42:.G7J'P\2HGE2A>;FR<S,;,B0(<N6+;M\^3+M5DL)Z&&8>[#G
M.C@X:'MUB#D]0_,D?F[<N %E.&3(EI:6[#Z')7?]^O50&TK.-) U3\[.SH&!
M@7OV["DO+Z<=6>M!\\2 YDG2U-34,/F_FYL;]_YA,#<W__###P\=.G3__GW:
M\?T/-$^DT"7S5%96=N'"A56K5O7ITX?4W%"&KGDJ*BHZ<^8,E \$[\/8V]M#
M61H3$R/"SZ#R!YHG=:!YTISGSY\O6K2(>U\I8VMKNV/'#MKQD0'-$W=TSSQ=
MOWX=9H6#@X.)B0GWN:&,&,P3 PP3#!:IN/[^][^?.'&BL+"PC7S^!,V35-BZ
M=:N%A06ID6(3%!24E965VPSLN3KPS:?R\G+('54E#U965JZNKE]__37W'VIL
M; P/#^=C4!B,C8V7+U_.#$U>7EY%147KVOGJU2NHXF[<N %7*/OOHWE2A>;F
MB0&VVNCHZ/S\_*JJ*MIMEP:W;MUJQ3E[4/A 71T0$"#:1\?0/(F?8\>.Z< Y
M>VP@:X6<' I;0T-#[G./ :XRF($E)26___X[[?A: YJG%R]>/'SX<.G2I6^<
M%6B>1 O9<_;T]?4[=^X\<.! */UH1_8G:)Y(H4OFB>'V[=MSYLSA[UX67?/$
MD)&1,67*E*Y=NQ)\NG3,F#%MY!CPER]?0KT6&QOK[.S,O=_0/*D#S1,7T#PI
M@^:)W1M2-T]E9650-*Y9LX;(4P#*Z*IYLK.S@]"8>XBT(Q,"-$]2@3_S!"N_
MO[__!\W ?)#Z&_H*A2(I*2DP,+#%(\+U]/0F39J4G)Q\[]X][K_%MWDR,#"
MNI$9&MCE4U-36]?.VMI:*,4G3)CPVL6.YDD5VIHG4U-3;V_OA0L7HBW0D-:9
MIYX]>ZY8L>+[[[\O*BJB'4'+H'D2/[IGGF"].G/F#-3+-C8VW.<>0_?NW?W\
M_.+CXZ$2IQU?:T#S=/SX\2E3IL!45_.%)P8T3Z*%K'F"(N*CCSXZ>?+DHT>/
M:$?V)VB>2*%[YJF\O!QRJO7KU[=X? 5WQ&">2DM++UZ\^/GGGT,Q3BJNMF.>
MKERY$A(2,FC0(")W2- \J:,MF"?(]B#&/GWZ$/QT*H.5E16,0G9VMJ0/$V!
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MJDR<?'KRY$EF9J:[N[L0BW1U=4>-&A45%<5& ]Z^?0N)A+FY.8-#J3DZ=.@
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M)0E\V+9MVP\^@5C%VX5.R7C__CV452DI*2*JO+*H/+U[]PYLC(N+:_%DNBA
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I!$$0!$$0!$$0!$$0!$$0!$&8X?\ 2H^E+*NNE34     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
